
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rupitasertib,Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evexta Bio Reports Progress On Rupitasertib for Advanced Breast Cancer
Details : Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2024
Lead Product(s) : Rupitasertib,Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
